Generated by AI
Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna uses its mRNA platform to design products that instruct cells to produce proteins or immune responses relevant to prevention and treatment. The company also works with manufacturing and commercialization capabilities to support product development and distribution across major healthcare markets. Headquartered in Cambridge, Massachusetts, Moderna plays a significant role in the biopharmaceutical industry by advancing a new class of medicines across vaccines and therapeutics.
Website325 Binney Street
Cambridge, MA, 02142
United States
The latest articles about MRNA.
Moderna (MRNA) stock falls for a seventh session, the longest losing streak since November 2024, as analysts cite valuation concerns after the YTD rally. Read more here.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about MRNA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.